-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $88

Benzinga·05/15/2026 17:31:44
Listen to the news
Evercore ISI Group analyst Maneka Mirchandaney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and lowers the price target from $89 to $88.